Money Trade Plan - A Blog To Share A High Profit Trading Signals In Forex, Stocks, Futures, Option Trading, ICO, BLOCKCHAIN And Bitcoin.Building the Perfect Master Plan

Tuesday, June 27, 2017

INVESTORS PICK: BUY MERIDIAN BIOSCIENCE, INC. ($VIVO) NASDAQ


Description

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal, viral, respiratory, and parasitic infectious diseases worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the illumigene brand; rapid immunoassays, a single-use immunoassays that can be used in point-of-care settings under the TRU, ImmunoCard, and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the Premier brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand. This segment’s products are primarily used in the detection of infectious diseases caused by various bacteria, viruses, parasites, and pathogens. Its products consists of C. difficile, a causative agent for antibiotic-associated diarrhea from a hospital-acquired infection; foodborne products, such as tests for Enterohemorrhagic E. coli and Campylobacter jejuni; Helicobacter pylori to detect stomach ulcers; respiratory products; and tests to detect Group B Streptococcu, Chlamydia trachomatis, Neisseria gonorrhea, and Herpes Simplex Virus Type 1 and Type 2. This segment sells its products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. Meridian Bioscience, Inc. was founded in 1976 and is headquartered in Cincinnati, Ohio.

Disclaimer: We're not suggesting buying this featured company specifically - only suggesting it for further investor research. 

VIVO$15.5000-0.1500% -0.9600Meridian Bioscience
Sector : MedicalIndustry : Medical Products
  • Signal
  • Short Term Trend
  • Long Term Trend
  • BUY
  • UP
  • DOWN
Day:-0.96%Wk:2.65%Mo:11.91%Yrly:-14.79%YTD:-12.43%
Strength Rank:26DIV%:3.24PE:21.46EPS:0.22ROE:18.02%
Ann EPS Gro:0.72%Last QTR EPS Gro:46.67%Sales Gro QTR:15.63%
Beta:0.96Mkt Cap:652MVolume:0.22MBook Value:3.96Ex:NASDAQ

Long Term Trend

The long term trend of Meridian Bioscience is DOWN indicating that VIVO has experienced a DOWN trend for at least the past 180 trading days. Long term trends are key to understanding the starting point to the path of least resistance of a stocks price trend. The expected future trend bias is always strongest with the current trend.

Short Term Trend

The short term trend of Meridian Bioscience is UPVIVO has been undergoing a short term UPUP over the past 7-10 days.

Signal

The current signal for Meridian Bioscience is BUY indicating that the stock could be Advancingin its trend. The current price trend is not Extreme. Stocks in extreme levels of price trend should be allowed to move out of the extreme range before a buy or sell decision should be made. As is the case for most trending momentum style stocks, much of the reason price action is not often known until well into the price trend. But earnings growth and management efficiency are key components to a foundation to a sustainable uptrend. We will focus on fundamental indications that can build a case for reasons why the stock should continue its current trend.

Strength Rank

Rank is the rank of the stock vs. its peers. For example a Rank of 98 means the stock is out performing 98% of its peers over a 12 month period. A rank of 2 means the stock is outperforming 2% of its peers, in other words, 98% of its peers are out performing it. 98 is good, 2 is not so good. The current quarter is 40% of the weighting, so current performance is more significant to the rank.

The current rank for Meridian Bioscience is 26, this means that VIVO is out performing 26% of its peers. Stocks that have a rank of 80 or better, with support of all other analyses shown here, tend to advance the trend.

The 90 day trend of Rank
ROE - Return on equity is a measure of financial efficiency, gauging how much profit a company is able to generate from the company financial net worth (that is, assets minus liabilities). Look for an annual return on equity of at least 20%. That is the level that set apart the winning stocks from the ordinary. That doesn't always mean that a company with smaller ROE is a poor investment. Some big winners have of course been shy of 20% return on equity when they started their major up trends. When ROE is strong, it gives investors an indication that the company is better poised to continue a solid earnings performance. A high ROE is only part of the fundamentals a solid company should have. Superb earnings and sales growth, superior profit margins and big operating cash flow are other key elements investors must seek.

The Current ROE for Meridian Bioscience is 18.02%, indicating VIVO is currently functioning with Average financial efficiency.

The 12 month chart trend of ROE
Annual EPS Growth - Companies with annual earnings growth of more than 20% are more likely to become leaders in up trending markets. While 20% Annual EPS growth is the minimum you should look for, don't be afraid to seek even better results. Studies have shown that the greatest winners in the past 30 years had an average 30% annual EPS growth rate when they started their strong up trends. You also can look for three straight years of rising EPS growth, with an average of at least 25%. These performance results often imply that a company is growing fast even if the general economy is slowing down or even in recession.

The current Annual EPS Growth for Meridian Bioscience is 0.72% which is less than the 30% average found is strong trending, fundamentally sound companies.

The 12 month chart trend of Annual EPS Growth
Quarterly EPS Growth - Outstanding earnings growth in the most recent quarters can be the single most important trait that identifies winners before they start their major price advances. Generally, the bigger the earnings growth, the better. Specifically, look for a company's earnings per share up at least 25-30% vs. the year-ago level in the most recent quarter or two. Gains of 50%, 100% or more are typical of strong market leaders even before they make their huge price moves. There's really nothing magic about this connection. Successful companies generate the strongest profit gains, regardless of the economic cycle. Even during periods when corporate profits are weak in general, you still find standouts that achieve massive earnings growth.

The current Quarterly EPS Growth for Meridian Bioscience is 46.67% which is greater than the 25% average found is strong trending stocks even during or before huge price moves.

The 12 month chart trend of Quarterly EPS Growth
Quarterly Sales growth - A company's annual and quarterly rate of increase in revenues (sales). A measure of growth and success as long as it is accompanied by an equally strong rate of increase in earnings per share. You want to see both in a potential investment. A company's quarterly EPS gain should be supported by an increase in revenue (sales) of at least 25% or at least by an acceleration in sales growth in the past few quarters. You also should watch out for earnings growth that comes amid falling sales. Companies with declining revenue often boost their EPS results through layoffs or other cost cuts, especially in an uncertain economic environment. But this isn't a sustainable approach, and it's definitely not as desirable as profit gains that come from higher revenue. Recent quarterly sales results are more critical when it comes to researching stocks.

The current Quarterly Sales Growth for Meridian Bioscience is 15.63% which is less than the 25% average found is strong trending stocks.

The 12 month chart trend of Quarterly Sales Growth

Dividend Yield

Dividend yield is the annual dividend income per share received from a company divided by its current share price. Normally investors would like to see a dividend yield between 2% and 20% for a dividend paying company. The dividend yield is an important factor to consider when investing in dividend paying stocks. Dividend yield is a financial ratio that reflects the % of profits a company makes of the dividend payments over the course of a year. For example if a stock pays an annual dividend of $2 and is trading at $50 a share, it would have a dividend yield of 4%.

The current Dividend Yield for Meridian Bioscience is 3.24%.


Stocks Historical Trading Characteristics.

           Trade Stats for   VIVO

Number of Trades6Trade Expectancy$26.21
Total Profit Amount$643.57Trade Expectancy%0.26%
Total Loss Amount$503.04Annual Trade Expectancy$131.07
Net Profit/Loss$140.53Annual Trade Expectancy%1.31%
Avg Profit on Winners$321.78Largest Profit$425.25
Avg Loss on Losers$125.76Largest Loss$288.69
Total Net % Gain or Loss1.41%Avg Days in Trade33
Avg % Gain on Winners3.34%Avg Days between Trades38
Avg % Loss on Losers1.28%Longest nbr of consecutive Winners2
Reward to Risk Ratio2.62Longest nbr of consecutive Losers4
Number of Trades Per Year5Largest Drawdown-5.03%
Number of Winners2Avg Drawdown-5.03%
Number of Losers4
Winning Percentage%33.33%



Backtesting a stock can provide investors with critical statistical data. These results give you an informed perspective on how a stock trades within your chosen buying and selling method of analysis. The definition of trade expectancy is defined as: trade expectancy = (probability of win * average win) - (probability of loss * average loss). If the calculation returns a positive number, a trader should make money over time.

The average percentage gained on positive, money making trades was 3.34%. While the average percent loss on money losing trades was 1.28%.

Trade expectancy includes both winners and losers. Trade expectancy is displayed as a percentage. This backtest displays the dollar value, percentage, annual trade expectancy, and annual percent. Annual expectancy is the trade expectancy percentage multiplied by the number of trades per year.

The Trade expectancy % for VIVO over the past year is 0.26%. The number of trades generated per year was 5 giving an Annual Trade Expectancy of 1.31%

The average days in a trade is 33 and the average days between trades is 38.

With any method of analysis that uses past performance, it can be said that past performance is not indication of future performance. What is does provide is a probabilistic look at a stock's price activity characteristics over time.



The historical Profit and loss curve of a $10,000 shows


Our Credo: What's Good for YOU!..Good For Us and vice versa!...

Disclaimers

Investing is Inherently Risky There are risks inherent in all investments, which may make such investments unsuitable for certain persons. These include, for example, economic, political, currency exchange, rate fluctuations, and limited availability of information on international securities. You may lose all of your money trading and investing. Do NOT enter any trade without fully understanding the worst-case scenarios of that trade. And do NOT trade with money you cannot afford to lose. Past performance of an investment is not necessarily indicative of its future results. No assurance can be given that any implied recommendation will be profitable or will not be subject to losses. Hypothetical Results Are Reported Results and examples used in the Company’s advertisements, books, videos, websites, and other media—including on the Site and the Network—are, in some cases, based on hypothetical (simulated) trades. Plainly speaking, these trades were not actually executed. Hypothetical performance results have certain limitations. Unlike an actual performance record, hypothetical results do not represent actual trading. Also, since the trades have not been executed, the hypothetical results may have under-or-over compensation for the impact, if any, of certain market factors, such as lack of liquidity. Hypothetical trading programs generally are also subject to the fact that they are designed with the benefit of hindsight. Hypothetical results also do not account for commissions or slippage. The Company’s simulations assume purchase and sale prices believed to be attainable. Yet traders are going to be getting into trades at different times and using various exit approaches, which may result in different pricing and outcomes. You may or may not receive the best available price on the purchase or the sale of a position in actual trading. Information provided by the Company is not investment advice. The Company is not a registered investment adviser, stock broker, or brokerage. You agree that the Company does not represent, warrant, or take responsibility that any account will or is likely to achieve profit or losses similar to those shown. Examples published by the Company are selected for illustrative purposes only. They are not typical and do not represent the typical results of all stocks within the Company’s software or its individual scans and searches. No independent party has audited any hypothetical performance contained at this Web site, nor has any independent party undertaken to confirm that they reflect the trading method under the assumptions or conditions specified.
Share:

0 comments:

Post a Comment

Powered by Myfxbook.com

Market Quotes are powered by Investing.com

SELECT YOUR LANGUAGE

BEST TECHNICAL ANALYSIS GURU

TELEGRAM JOIN NOW : professional trader and trainer ... forex,stocks,commodity, cryptocurrency,futures,options,etc contact me :

Google+ Followers

Powered by Blogger.

Blog Archive

Follow by Email

Video Of Day

Links

Theme Support